Skip to main content
Illustration of SpaceOAR Hydrogel

SpaceOAR Vue™ Hydrogel for Urology

The only iodinated hydrogel spacer for prostate cancer radiation therapy

Designed for enhanced visibility via CT scan

Visible on a CT scan, SpaceOAR Vue™ Hydrogel is designed to aid in visualization of the target region, enabling efficient patient positioning for radiation treatment.¹ In Dr. Randall Brenneman’s and Dr. Brian Baumann’s experience, SpaceOAR Vue Hydrogel appears (or seems) to polymerize slightly slower compared to SpaceOAR “making it more forgiving with regards to suboptimal placement in the perirectal space.”²

SpaceOAR Vue Hydrogel could be a suitable imaging option for prostate cancer patients or patients with implanted metallic devices who cannot undergo an MRI. It may also reduce the need for post-implant MRI scans leading to cutting out-of-pocket costs for patients.¹

Physician perspective

See how SpaceOAR Vue Hydrogel can benefit your patients and practice

Dr. Bill Johnson
Exeter Hospital, New Hampshire

Interested in streamlining your prostate cancer treatment planning?

Connect with our team to learn more about SpaceOAR Vue Hydrogel, schedule a demo, or get answers to your questions.
“I think the paramount reason to use SpaceOAR Vue is an ability to view your results easily. It’s cost-effective for patients to get a post-procedural CT scan as opposed to an MRI.”

Learn more about SpaceOAR Vue Hydrogel

Connect with our team for answers to your questions or to schedule a demo.

Get the latest clinical data, training materials, and more.

   

 

References

  1. Data on file with Boston Scientific.
  2. Brenneman RJ, Baumann BC. SpaceOAR Vue Hydrogel: The Next- Generation Radiopaque Hydrogel Spacer. https://www.bostonscientific.com/en-US/medical-specialties/urology/prostate-health/prostate-cancer/spaceoar-hydrogel/clinical-results/spaceoar-vue-hydrogel.html. Accessed October 28, 2022.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the use of referenced technologies but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case.

Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Case studies are not necessarily representative of clinical outcomes in all cases as individual results may vary.

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

SpaceOAR Vue Hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Vue Hydrogel to reduce the radiation dose delivered to the anterior rectum.

SpaceOAR Vue Hydrogel contains polyethylene glycol (PEG) and iodine.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.

As with any medical treatment, there are some risks involved with the use of SpaceOAR Vue Hydrogel. Potential complications associated with SpaceOAR Vue Hydrogel include, but are not limited to: pain associated with SpaceOAR Vue Hydrogel injection, pain or discomfort associated with SpaceOAR Vue Hydrogel, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope, and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989810-AB

Dr. Johnson is a Boston Scientific consultant and was compensated for his contributions.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

© 2022 Boston Scientific Corporation or its affiliates. All rights reserved.